Free Trial
NASDAQ:ADMA

ADMA Biologics Q2 2025 Earnings Report

ADMA Biologics logo
$16.74 -0.85 (-4.83%)
Closing price 04:00 PM Eastern
Extended Trading
$16.61 -0.13 (-0.75%)
As of 05:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ADMA Biologics EPS Results

Actual EPS
N/A
Consensus EPS
$0.14
Beat/Miss
N/A
One Year Ago EPS
N/A

ADMA Biologics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

ADMA Biologics Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Thursday, August 7, 2025
Conference Call Time
4:30PM ET

Conference Call Resources

ADMA Biologics Earnings Headlines

ADMA Biologics, Inc. Rings the Opening Bell
I was wrong about Trump
I made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his advisors, I believed him. I believed the promise that he would finally confront the single most dangerous threat to American life. That he would fix the ticking time bomb I’ve been warning about for 15 years. But I was wrong.
ADMA Biologics Inc Dividends - Morningstar
ADMA Biologics Inc Valuation - Morningstar
See More ADMA Biologics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like ADMA Biologics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ADMA Biologics and other key companies, straight to your email.

About ADMA Biologics

ADMA Biologics (NASDAQ:ADMA), Inc. is a biopharmaceutical company focused on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment and prevention of immune deficiencies and infectious diseases. Through its wholly owned plasma collection and manufacturing facilities, the company produces human immunoglobulin therapies designed to provide critical antibody support to patients with primary immunodeficiency disease and those at heightened risk for certain viral and bacterial infections.

The company’s principal commercial products include BIVIGAM, a 10% intravenous immunoglobulin (IVIG) therapy indicated for primary humoral immunodeficiency, and ASCENIV, a 10% IVIG hyperimmune globulin with elevated titers of antibodies against respiratory syncytial virus (RSV) and other respiratory pathogens. Both therapies are marketed in the United States and distributed through specialty pharmacies and hospitals. ADMA Biologics also maintains a proprietary plasma collection network that supplies raw material for its clinical and commercial programs.

Founded in 2006 and headquartered in Ramsey, New Jersey, ADMA Biologics expanded its operational footprint with a state-of-the-art plasma fractionation facility in Boca Raton, Florida. This facility supports scalable manufacturing capacity and enables the company to pursue additional late-stage clinical programs, including novel hyperimmune globulins targeting emerging viral infections. Over the years, ADMA has secured regulatory approvals, built strategic alliances for plasma sourcing, and strengthened its balance sheet through public offerings and private placements.

Under the guidance of a management team with extensive expertise in plasma biomanufacturing, regulatory affairs and commercial operations, ADMA Biologics continues to broaden its product portfolio and geographic reach. The company is committed to enhancing patient access to life-saving immunoglobulin therapies and advancing its pipeline to address unmet medical needs in immunology and infectious disease worldwide.

View ADMA Biologics Profile

More Earnings Resources from MarketBeat